 STATEN ISLAND, N.Y., June 29, 2021 PRNewswire -- Acurx Pharmaceuticals, Inc. Nasdaq: ACXP the Company, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares of common stock, at a price to the public of 6.00 per share. 